Lista de obras - María José Buzón - Dominio Público Uruguay

A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers

artículo científico publicado en 2014

A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors

artículo científico publicado en 2011

Broad activation of latent HIV-1 in vivo

artículo científico publicado en 2016

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

artículo científico publicado en 2018

Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes

article

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection

artículo científico publicado en 2009

Correction: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

artículo científico publicado en 2016

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

artículo científico publicado en 2011

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

artículo científico publicado en 2014

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure

artículo científico publicado en 2010

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification

artículo científico publicado en 2013

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

artículo científico publicado en 2013

Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

scientific article published on 20 May 2009

Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence

artículo científico publicado en 2018

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

artículo científico publicado en 2019

HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation

article

HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation

artículo científico publicado en 2012

HIV-1 persistence in CD4+ T cells with stem cell-like properties

artículo científico publicado en 2014

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

artículo científico publicado en 2010

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients

artículo científico publicado en 2013

Immuno-modulatory strategies for reduction of HIV reservoir cells

artículo científico publicado en 2015

Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

artículo científico publicado en 2010

Inhibition of HIV-1 Integration in Ex Vivo -Infected CD4 T Cells from Elite Controllers ⬇️

artículo científico publicado el 6 de julio de 2011

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat

artículo científico publicado en 2015

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

artículo científico publicado en 2016

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

artículo científico publicado en 2014

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

scientific article published on 02 August 2016

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations

scientific article published on 19 August 2019

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells

artículo científico publicado en 2014

Metabolic pathway activation distinguish transcriptional signatures of CD8+ T cells from HIV-1 elite controllers

article

Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

artículo científico publicado en 2013

Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

artículo científico publicado en 2012

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

artículo científico publicado en 2014

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers

artículo científico publicado en 2015

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

artículo científico publicado en 2012

Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

artículo científico publicado en 2008

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation

artículo científico publicado en 2013

Recommendations for measuring HIV reservoir size in cure-directed clinical trials

artículo científico publicado en 2020

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

scientific article published on 18 October 2019

Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells

artículo científico publicado en 2014

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates

artículo científico publicado en 2010

Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers

artículo científico publicado en 2010

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.

artículo científico publicado en 2008

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

artículo científico

Lista de obras de María José Buzón

A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers

A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors

Broad activation of latent HIV-1 in vivo

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection

Correction: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation

HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation

HIV-1 persistence in CD4+ T cells with stem cell-like properties

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients

Immuno-modulatory strategies for reduction of HIV reservoir cells

Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Inhibition of HIV-1 Integration in Ex Vivo -Infected CD4 T Cells from Elite Controllers ⬇️

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells

Metabolic pathway activation distinguish transcriptional signatures of CD8+ T cells from HIV-1 elite controllers

Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation

Recommendations for measuring HIV reservoir size in cure-directed clinical trials

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates

Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.